Alzamend Neuro, Inc. is an early clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for neurodegenerative and psychiatric illnesses. Its development pipeline features two key candidates. AL001, currently in Phase II clinical trials, administers a proprietary blend of lithium, proline, and salicylate. This compound is designed to address a broad spectrum of conditions such as Alzheimer's, bipolar disorder, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and other neurodegenerative or psychiatric conditions. Also in its portfolio is AL002, which has successfully completed its preclinical phase. AL002 represents a cell-based therapeutic vaccine strategy, employing mutant-peptide sensitized cells to restore and enhance a patient's immune system in its fight against Alzheimer's disease. Incorporated in 2016, Alzamend Neuro, Inc. maintains its headquarters in Atlanta, Georgia.
